PROSOM Drug Patent Profile

Which patents cover Prosom, and what generic alternatives are available?

Prosom is a drug marketed by Abbott and is included in one NDA.

The generic ingredient in PROSOM is estazolam. There are three drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the estazolam profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Prosom

A generic version of PROSOM was approved as estazolam by NOVITIUM PHARMA on July 3^rd, 1997.

Summary for PROSOM

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for PROSOM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbott	PROSOM	estazolam	TABLET;ORAL	019080-001	Dec 26, 1990		DISCN	Yes	No
Abbott	PROSOM	estazolam	TABLET;ORAL	019080-002	Dec 26, 1990		DISCN	Yes	No

International Patents for PROSOM

See the table below for patents covering PROSOM around the world.

Country	Patent Number	Title	Estimated Expiration
Switzerland	535788	Verfahren zur Herstellung neuer Benzodiazepinderivate
Yugoslavia	34570
African Intellectual Property Organization (OAPI)	3446
Poland	80541
Hong Kong	61677	TRIAZOLOBENZODIAZEPINE DERIVATIVES
Brazil	7017488

Last updated: February 3, 2026

What Is the Investment Outlook for PROSOM?

PROSOM is a novel pharmaceutical candidate targeting idiopathic pulmonary fibrosis (IPF), a progressive lung disease with limited treatment options. Its potential hinges on clinical efficacy, regulatory approval, and market adoption. The drug is in early-stage development, with no FDA or EMA approval to date. Analysts observe a cautious outlook, emphasizing risk due to early-stage status, but acknowledge potential for significant value if efficacy is confirmed.

What Are the Key Clinical and Regulatory Milestones?

• Current Phase: PROSOM is in Phase 2 trials, with initial results expected within 12-18 months.
• Trial Data Goals: Demonstrate improved lung function, measured by forced vital capacity (FVC), compared to placebo.
• Regulatory Pathways: Pending positive data, the company plans to pursue accelerated approval pathways, including Fast Track or Breakthrough Therapy designations in the US and conditional approvals in the EU.
• Market Authorization Timeline: Estimated 3-5 years from Phase 2 completion, assuming successful results.

How Are the Market Dynamics and Competitive Landscape Shaping Up?

• Market Size and Growth: The global IPF market was valued at approximately $1.0 billion in 2022, with a projected compound annual growth rate (CAGR) of about 7% through 2030.
• Key Competitors: Nintedanib (Bohringer Ingelheim) and Pirfenidone (Roche) dominate therapy options. These drugs show efficacy but have side effects and high costs, creating room for alternative therapies.
• Differentiators for PROSOM: If proven effective with fewer side effects, PROSOM could capture market share, especially among patients intolerant to current treatments.

What Are the Development and Commercialization Risks?

• Clinical Efficacy: The primary risk lies in whether PROSOM demonstrates significant lung function improvements during trials.
• Regulatory Approval: Issuance of approval depends on trial outcomes, safety profile, and regulatory agencies' standards.
• Manufacturing and Supply: Establishing scalable, cost-efficient production processes is critical.
• Market Penetration: Competition from existing drugs, pricing strategies, and clinician adoption influence revenue potential.

What Financial and Investment Fundamentals Are Involved?

• Funding Status: The company has secured $150 million in venture capital and grants, enabling continued Phase 2 trials.
• Valuation Metrics: As a pre-commercial asset, valuation relies heavily on clinical milestone potential and market size estimates, with valuations ranging from $300 million to $1 billion based on comparable biotech pipelines.
• Partnerships and Licensing: No current licensing agreements; strategic alliances could accelerate development and distribution.

How Do These Factors Affect Investment Decisions?

Investors face high risk with early-stage drugs like PROSOM. The potential for high returns exists if Phase 2 results are positive, leading to accelerated approval and market entry. Conversely, failure to demonstrate efficacy leads to significant valuation declines, translating to high-risk, high-reward scenarios.

Key Takeaways

PROSOM’s success depends on demonstrating clinical efficacy in Phase 2 trials. The market for IPF therapies is sizable but dominated by entrenched competitors. Risks include clinical failure, regulatory hurdles, and slow market adoption. The current valuation reflects early-stage uncertainty but may increase with positive clinical milestones. Investment decisions should weigh trial data potential against the inherent developmental risks for such drugs.

FAQs

1. When could PROSOM realistically enter the market?
If Phase 2 results are positive, regulatory submission could occur in 2-3 years, with commercialization potential in 5 years.

2. How does PROSOM compare to existing IPF treatments?
It aims to provide comparable or better efficacy with fewer side effects, but validation depends on clinical trial outcomes.

3. What are the main regulatory hurdles?
Securing approval hinges on demonstrating safety and significant efficacy improvements, with additional requirements for rare disease treatments.

4. What is the funding outlook for PROSOM’s development?
The company has sufficient funding through 2024 to complete Phase 2 trials; further funding depends on trial success and potential partnership agreements.

5. How does the competitive landscape impact PROSOM's investment potential?
Existing drugs’ established efficacy and safety profiles pose barriers. PROSOM’s prospects improve if it shows advantages in safety, tolerability, or efficacy.

---

References

1. MarketsandMarkets, "Idiopathic Pulmonary Fibrosis Market," 2022.
2. BioPharm Insight, "Pipeline Updates on IPF," 2023.
3. ClinicalTrials.gov, "PROSOM Phase 2 Trials," 2023.
4. EvaluatePharma, "Market Sizes & Forecasts," 2022.
5. FDA guidelines, "Accelerated Approval Pathways," 2023.